MedTrace Logo

Evaluation of the Efficacy and Safety of LevoCept

NCT02882191 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 279

Last updated 2026-04-23

Study results available
· View outcomes & findings →

Summary

To evaluate the effectiveness, device placement, safety, and tolerability of LevoCept to support commencing a Phase III Clinical Study

Conditions

  • Contraception

Interventions

DRUG

LevoCept

placement of LevoCept IUD

Sponsors & Collaborators

  • Synteract, Inc.

    collaborator INDUSTRY

  • Sebela Women's Health Inc.

    lead INDUSTRY

Principal Investigators

  • David Turok, MD · University of Utah

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2018-07-17
Completion
2020-11-12
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02882191 on ClinicalTrials.gov